Skip to content

NGM Bio a stock to watch ahead of key NASH presentation

August 18, 2020

NGM Biopharmaceuticals (NASDAQ:NGM) announces that comprehensive data from its 24-week Phase 2 clinical trial evaluating aldafermin in patients with nonalcoholic steatohepatitis (NASH) will be featured in an oral plenary session at the virtual International Liver Congress on August 29.

The event could cause a significant swing in shares considering past data announcements.

In October 2019, the stock sold off after it released preliminary data from the study that were shy of Viking Therapeutics’ (NASDAQ:VKTX) VK2809 but comparable to Madrigal Pharmaceuticals’ (NASDAQ:MDGL) MGL-3196.

In February, shares rallied after the company announced positive data from cohort 4.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: